{
    "nct_id": "NCT04515628",
    "official_title": "An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Assess the Effect of Steady-State Branebrutinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants",
    "inclusion_criteria": "* Healthy participant, as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations by investigator\n* Body mass index (BMI) of 18.0 kg/m2 to 32.0 kg/m2, inclusive, as measured at screening visit\n* Women and men must agree to follow specific methods of contraception, if applicable, while participating in the trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 50 Years",
    "exclusion_criteria": "* Women who are of childbearing potential\n* Women who are pregnant or breastfeeding\n* Any significant acute or chronic medical illness that presents a potential risk to the participant in the opinion of the investigator and/or may compromise the objectives of the study, including a history of or active liver disease\n* Any other sound medical, psychiatric, and/or social reason as determined by the investigator\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}